CN1041793C - 氟化氯霉素药物组合物 - Google Patents

氟化氯霉素药物组合物 Download PDF

Info

Publication number
CN1041793C
CN1041793C CN91108502A CN91108502A CN1041793C CN 1041793 C CN1041793 C CN 1041793C CN 91108502 A CN91108502 A CN 91108502A CN 91108502 A CN91108502 A CN 91108502A CN 1041793 C CN1041793 C CN 1041793C
Authority
CN
China
Prior art keywords
pyrrolidone
weight
composition
polyethylene glycol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN91108502A
Other languages
English (en)
Other versions
CN1059276A (zh
Inventor
H·M·阿佩利安
D·科芬-比奇
A·S·哈格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24296100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1041793(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1059276A publication Critical patent/CN1059276A/zh
Application granted granted Critical
Publication of CN1041793C publication Critical patent/CN1041793C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

公开了一种兽用注射药物组合物，它含有氟化氯霉素、N-甲基-2-吡咯烷酮、聚乙二醇和减粘剂。该组合物具有化学和物理稳定性，呈现恒定的血药浓度，不产生不良副作用。

Description

氟化氯霉素药物组合物
本发明涉及含有氟化氯霉素(florfenicol)作为活性成分的药物组合物，特别是涉及含有高浓度氟化氯霉素的注射用组合物。
氟化氯霉素(D-(苏型)-1-对甲磺酰苯基-2-二氯乙酰氨基-3-氟-1-丙醇)是已知抗菌剂，可用于兽医学目的。当治疗大动物时，有时期望施用含有高浓度氟化氯霉素的组合物。那么，如此大剂量施用的氟化氯霉素最好应该能显示出恒定的血药浓度，并且在长时间内保持其活性。
氟化氯霉素水溶性差(约1．3mg／ml)，由于按治疗剂量给药所需体积很大，要配制其浓缩水溶液注射液是不现实的。
在许多药用有机溶剂中，氟化氯霉素的溶解度也很低，这些溶剂的例子有1，2-丙二醇、甘油、苯甲醇等。
氟化氯霉素一般可溶于非质子性极性溶剂，例如N-甲基-2-吡咯烷酮或2-吡咯烷酮，然而，在用于肌肉注射时，这些溶剂的浓度高于30％时会引起注射部位发炎和组织损伤。
已发现利用包含下列组分的新组合物可提供稳定的氟化氯霉素注射用组合物：
10-50％(重量)氟化氯霉素；
10-65％(重量)吡咯烷酮类溶剂；
5-15％(重量)减粘剂；
5-40％(重量)聚乙二醇。
这种新组合物在长时间内保持恒定的血药浓度并且表现出良好的物理和化学稳定性。
图1解释单次肌肉注射20mg／kg的剂量之后，小牛血清中氟化氯霉素的浓度。
氟化氯霉素呈现抗菌活性，可用于兽药(Merk Index，11th Edition，No．4042)。美国专利4，235，892叙述了该化合物及其制备方法，该专利在此列为参考。
本发明制得了一种新组合物，在该组合物中，氟化氯霉素以较高的浓度存在于一种独特的有机溶剂系统中，该有机溶剂系统由一种吡咯烷酮类溶剂(例如2-吡咯烷酮、N-甲基-2-吡咯烷酮)、聚乙二醇和一种减粘剂组成。
本发明组合物可包含10-50％，优选20-40％(重量)的氟化氯霉素。
可用于本发明的吡咯烷酮类溶剂包括2-吡咯烷酮和N-甲基-2-吡咯烷酮。优选溶剂为N-甲基-2-吡咯烷酮。本发明组合物中吡咯烷酮类溶剂的重量可占组合物总重量的10-65％。在给牛进行肌肉注射时，N-甲基-2-吡咯烷酮溶剂含量超过30％(重量)的组合物会造成注射部位发炎和组织损伤。
本发明组合物所用的聚乙二醇包括平均分子量为200-400的聚乙二醇，优选聚乙二醇的平均分子量约为300，也称为PEG300。本发明组合物中聚乙二醇的量为5-45％，优选30-40％(重量)。
由于本发明组合物中固体氟化氯霉素含量高，需要加入减粘剂以制得一种可用于注射的产品。本发明所用减粘剂的例子包括乙醇和丙二醇，优选的减粘剂是丙二醇。本发明组合物中减粘剂的用量为组合物重量的5-15％，优选10-15％。
将吡咯烷酮类溶剂、减粘剂与约90％的聚乙二醇组分混合，然后将氟化氯霉素溶解在该溶液中，并用剩余的聚乙二醇调整体积，所得澄清溶液经过滤灭菌，由此很容易制得本发明组合物。
本发明组合物所显示出的理想特性可使氟化氯霉素以比较高的浓度施用。该组合物具有理想的粘度特征，因此可在很宽的温度范围保持良好的可注射性并易于处理，例如通过灭菌滤膜的流速适宜。该组合物还具有物理和化学稳定性，如，在2℃-30℃下贮存时，该组合物可稳定并保持其特性至少两年。该组合物可在长时间内提供有治疗作用的血药浓度，还表现出可接受的组织耐受性。
下列实施例详细阐述了本发明。在不偏离本公开的目的和意图的前提下，可以进行各种改进，这对本领域技术人员是显而易见的。
                      实施例1
由下列成分配制注射液：
成分                                重量／ml
氟化氯霉素                          300mg
N-甲基-2-吡咯烷酮                   250mg
丙二醇                              150mg
聚乙二醇300                         加至1ml
该溶液按下述程序配制：将N-甲基-2-吡咯烷酮、丙二醇和占所需量约90％的聚乙二醇300充分混合，然后将氟化氯霉素溶解在该混合物中。用剩余的聚乙二醇300调整体积，并将澄清溶液过滤灭菌。
对牛以20mg／kg氟化氯霉素的单次剂量肌肉注射上述制剂，所得血清药物浓度如下：
浓度(最大)                       3．86μg／ml
浓度(12小时)                     1．94μg／ml
浓度(24小时)                     1．03μg／ml
                  实施例2
由下列成分配制注射液：
成分                             重量／ml
氟化氯霉素                       300mg
N-甲基-2-吡咯烷酮                250mg
乙醇                             100mg
聚乙二醇300                      加至1ml
该溶液按下述程序配制：将N-甲基-2-吡咯烷酮、乙醇和占所需量约90％的聚乙二醇300充分混合，然后将氟化氯霉素溶解在该混合物中。用剩余的聚乙二醇300调整体积，将澄清溶液过滤灭菌。
                  实施例3
由下列成分配制注射液：
成分                             重量／ml
氟化氯霉素                       300mg
N-甲基-2-吡咯烷酮                350mg
丙二醇                           150mg
聚乙二醇300                      加至1ml
该溶液按实施例1所述方法配制。
对牛以20mg／kg氟化氯霉素的单次剂量肌肉注射上述制剂，所得血清药物浓度如下：
浓度(最大)                        5．80μg／ml
浓度(12小时)                      1．80μg／ml
浓度(24小时)                      0．60μg／ml
                    实施例4
由下列成分配制注射液：
成分                              重量／ml
氟化氯霉素                        300mg
N-甲基-2-吡咯烷酮                 350mg
乙醇                              100mg
聚乙二醇300                       加至1ml
该溶液按实施例2所述方法配制。

Claims (8)

1．一种制备兽医用药物组合物的方法，该组合物包含：
10-50％(重量)氟化氯霉素；
10-65％(重量)吡咯烷酮类溶剂；
 5-15％(重量)减粘剂；
 5-40％(重量)聚乙二醇；该方法包括：将吡咯烷酮类溶剂和减粘剂与大约90％的聚乙二醇组分混合，然后将氟化氯霉素溶于所得到的混合物中，用其余的聚乙二醇调整体积，过滤灭菌。
2．权利要求1的方法，其中吡咯烷酮类溶剂选自2-吡咯烷酮和N-甲基-2-吡咯烷酮。
3．权利要求2的方法，其中吡咯烷酮类溶剂为N-甲基-2-吡咯烷酮。
4．权利要求1的方法，其中聚乙二醇的平均分子量在200和400之间。
5．权利要求4的方法，其中聚乙二醇的平均分子量为300。
6．权利要求1的方法，其中减粘剂选自乙醇和丙二醇。
7．权利要求6的方法，其中减粘剂为丙二醇。
8．权利要求1的方法，其中使用下列成分：
重量／ml                           成分
300mg                              氟化氯霉素
250mg                              N-甲基-2-吡咯烷酮
150mg                              丙二醇
加至1ml                            聚乙二醇300
CN91108502A 1990-08-29 1991-08-28 氟化氯霉素药物组合物 Expired - Lifetime CN1041793C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US574,430 1990-08-29
US07/574,430 US5082863A (en) 1990-08-29 1990-08-29 Pharmaceutical composition of florfenicol

Publications (2)

Publication Number Publication Date
CN1059276A CN1059276A (zh) 1992-03-11
CN1041793C true CN1041793C (zh) 1999-01-27

Family

ID=24296100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN91108502A Expired - Lifetime CN1041793C (zh) 1990-08-29 1991-08-28 氟化氯霉素药物组合物

Country Status (29)

Country Link
US (1) US5082863A (zh)
EP (1) EP0546018B1 (zh)
JP (1) JPH0692299B2 (zh)
KR (1) KR960005705B1 (zh)
CN (1) CN1041793C (zh)
AT (1) ATE112959T1 (zh)
AU (1) AU655935B2 (zh)
CA (1) CA2090422C (zh)
CZ (1) CZ280541B6 (zh)
DE (1) DE69104724T2 (zh)
DK (1) DK0546018T3 (zh)
ES (1) ES2065059T3 (zh)
FI (1) FI101596B1 (zh)
HK (1) HK185896A (zh)
HU (1) HU213406B (zh)
IE (1) IE66925B1 (zh)
IL (1) IL99337A (zh)
MX (1) MX9100855A (zh)
MY (1) MY106780A (zh)
NO (1) NO301746B1 (zh)
NZ (1) NZ239559A (zh)
PL (1) PL171466B1 (zh)
PT (1) PT98790B (zh)
RU (1) RU2085191C1 (zh)
SK (1) SK279290B6 (zh)
TW (1) TW215054B (zh)
UA (1) UA27244C2 (zh)
WO (1) WO1992004016A1 (zh)
ZA (1) ZA916780B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060310C (zh) * 1994-12-04 2001-01-10 张长兴 一种防治病害的农药
IL124454A (en) * 1995-12-21 2003-10-31 Pfizer Injectable danofloxacin formulations
US5993116A (en) * 1997-06-30 1999-11-30 Sandvik Rock Tools, Inc. Filler-containing rock bolt anchoring system and method of preparation thereof
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
US20030068339A1 (en) * 2001-10-02 2003-04-10 Phoenix Scientific, Inc. Veterinary florfenicol formulation that is syringeable under cold weather conditions
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
CN1649829A (zh) * 2002-03-08 2005-08-03 先灵-普劳有限公司 新型氟苯尼考类抗生素
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
KR20040015624A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
KR20040015623A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 주사액 조성물
KR20040020086A (ko) * 2002-08-29 2004-03-09 주식회사 성원 축산 동물의 호흡기 질병 예방 및 치료용 조성물
UA82359C2 (uk) * 2003-04-03 2008-04-10 Schering Plough Ltd Композиція (варіанти) і спосіб лікування мікробних і паразитних інфекцій у великої рогатої худоби і інших тварин
AR044437A1 (es) * 2003-05-29 2005-09-14 Schering Plough Ltd Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
ES2266695T3 (es) 2003-07-31 2007-03-01 Emdoka Bvba, Drug Registration And Marketing Suspensiones acuosas inyectables para uso veterinario que contienen florfenicol.
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US7126005B2 (en) 2003-10-06 2006-10-24 Aurobindo Pharma Limited Process for preparing florfenicol
PL1830885T3 (pl) 2004-12-21 2009-04-30 Intervet Int Bv Iniekcyjna kompozycja weterynaryjna zawierająca florfenikol
KR100645268B1 (ko) * 2005-04-04 2006-11-14 주식회사 고려비엔피 동물약품용 약제학적 조성물
KR100712928B1 (ko) * 2005-08-24 2007-05-02 엘지전자 주식회사 혼합형 유니터리 공기조화장치의 압축기 선택 운전방법
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
KR100748251B1 (ko) * 2006-05-08 2007-08-10 주식회사 삼양애니팜 플로르페니콜 함유 주사용 조성물
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
US8084643B2 (en) * 2006-12-13 2011-12-27 Intervet Inc. Water-soluble prodrugs of florfenicol and its analogs
CA2672795A1 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof
US7550625B2 (en) * 2007-10-19 2009-06-23 Idexx Laboratories Esters of florfenicol
PE20091171A1 (es) * 2007-12-14 2009-08-03 Schering Plough Ltd Proceso para recuperar florfenicol y analogos de florfenicol
CA2732017A1 (en) * 2008-07-30 2010-02-04 Intervet International B.V. Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
BRPI1002021A2 (pt) 2010-01-21 2012-05-22 Nanocore Biotecnologia S A composições farmacêuticas para tratamento de infecções bacterianas
BRPI1002023A2 (pt) * 2010-03-01 2011-10-25 Nanocore Biotecnologia S A forma farmacêutica sólida de dissolução rápida para tratamento de infecções bacterianas
CN102973498A (zh) * 2012-12-13 2013-03-20 江苏恒丰强生物技术有限公司 一种氟苯尼考注射液及其制备方法
EP2995297A1 (fr) 2014-09-09 2016-03-16 Ceva Sante Animale Compositions parentérales et leurs utilisations
KR101642717B1 (ko) * 2015-11-13 2016-07-27 바이엘코리아주식회사 플로르페니콜을 포함하는 주사용 조성물
CN107582522A (zh) * 2017-11-02 2018-01-16 山东谊源动物药业有限公司 一种氟苯尼考注射液的生产工艺
JP7532341B2 (ja) * 2018-09-06 2024-08-13 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド 注射可能な徐放性の抗生物質製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
US4423040A (en) * 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERCK LNDEX 11版,NO.4042 1989.1.1 Merck co.lnc *

Also Published As

Publication number Publication date
CA2090422C (en) 1996-02-13
FI101596B (fi) 1998-07-31
CZ25793A3 (en) 1993-10-13
SK279290B6 (sk) 1998-09-09
HK185896A (en) 1996-10-11
UA27244C2 (uk) 2000-08-15
FI930844A0 (fi) 1993-02-25
PL171466B1 (pl) 1997-05-30
ZA916780B (en) 1993-03-01
WO1992004016A1 (en) 1992-03-19
FI930844A (fi) 1993-02-25
PT98790B (pt) 1999-01-29
HUT63558A (en) 1993-09-28
MX9100855A (es) 1992-04-01
MY106780A (en) 1995-07-31
KR960005705B1 (ko) 1996-05-01
NO930616D0 (no) 1993-02-22
DK0546018T3 (da) 1994-11-28
DE69104724T2 (de) 1995-02-16
DE69104724D1 (de) 1994-11-24
US5082863A (en) 1992-01-21
HU9300555D0 (en) 1993-05-28
IE913024A1 (en) 1992-03-11
FI101596B1 (fi) 1998-07-31
IE66925B1 (en) 1996-02-07
NO930616L (no) 1993-02-22
JPH0692299B2 (ja) 1994-11-16
JPH05506245A (ja) 1993-09-16
CN1059276A (zh) 1992-03-11
AU8436691A (en) 1992-03-30
IL99337A (en) 1995-05-26
AU655935B2 (en) 1995-01-19
ATE112959T1 (de) 1994-11-15
PT98790A (pt) 1992-07-31
EP0546018B1 (en) 1994-10-19
EP0546018A1 (en) 1993-06-16
IL99337A0 (en) 1992-07-15
CZ280541B6 (cs) 1996-02-14
HU213406B (en) 1997-06-30
RU2085191C1 (ru) 1997-07-27
NZ239559A (en) 1992-11-25
NO301746B1 (no) 1997-12-08
TW215054B (zh) 1993-10-21
CA2090422A1 (en) 1992-03-01
SK12993A3 (en) 1993-07-07
ES2065059T3 (es) 1995-02-01

Similar Documents

Publication Publication Date Title
CN1041793C (zh) 氟化氯霉素药物组合物
EP0441307B1 (en) Syrup composition
CN1191826C (zh) 药物制剂
CN1767815A (zh) 非水单相载体和使用这类载体的制剂
CN1711996A (zh) 含有双氯芬酸钠和β－环糊精的可注射药物组合物
CN1917883A (zh) 曲前列环素改善肾功能的用途
EP1830885B1 (en) Injectable veterinary composition comprising florfenicol
CN1635880A (zh) 双胍衍生物在制备具有瘢痕形成作用的医药产品中的应用
JPH01287041A (ja) 徐放性製剤
CN1775214A (zh) 利福喷丁、利福平、利福布丁或利福定注射剂及其制备方法
RU2397753C1 (ru) Композиция для лечения бактериальных инфекций у животных
CN1065010A (zh) 甾类化合物的组合物
US4389414A (en) Prostaglandin compositions
US4032645A (en) Injectable metronidazole composition
CN1304727A (zh) 一种以苯甲酸苄酯或氮酮为助溶剂的含阿维菌素或伊维菌素的注射液
KR940000066B1 (ko) 약제학적 제제
CN1814297A (zh) 阿昔洛韦在注射液中的增溶方法
KR100439853B1 (ko) 플로르페니콜의 약제학적 조성물
CN117503732A (zh) 一种5-ht3受体拮抗剂透皮贴剂及其制备方法
KR20020006555A (ko) 국소마취제를 함유하는 외용 겔제제
CN1575794A (zh) 含丙硫咪唑亚砜的液体制剂
KR20050103357A (ko) 플로르페니콜의 약제학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20110828

Granted publication date: 19990127